Clinical Trials · NCT00068029
Pegvisomant And Sandostatin LAR Combination Study
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 75
- Start date
- Oct 2003
- Locations
- 33 sites, 12 countries
- Primary endpoint
- Number of subjects experiencing treatment-emergent adverse events across the duration fo the study